18F-氟雌二醇研究进展
18F-16α-氟雌二醇(18F-FES)是一种与雌激素受体(ER)结合的PET显像剂,2016年在法国、2020年在美国获批用于ER阳性转移性或复发性乳腺癌。2023年SNMMI发布适用标准,明确18F-FES PET/CT的四个适用指征。本文综述其显像基础、正常分布、假阳性与假阴性及最新临床应用。
要点
- 18F-FES PET/CT已于2016年在法国、2020年在美国获批用于ER阳性转移性或复发性乳腺癌。
- 18F-FES PET/CT评估的ER阳性可作为生物标志物,识别可能对内分泌治疗有反应和不 unlikely 有反应的转移性乳腺癌患者。
- SNMMI 2023年适用标准列出四个适用指征:活检困难或活检无诊断结果时评估转移灶功能性ER状态、其他影像检查不明确或可疑时检测ER状态、转移性疾病初始诊断、转移性疾病进展时考虑内分泌治疗。
核心结论
- 18F-FES PET/CT评估的ER阳性可作为生物标志物,识别可能对内分泌治疗有反应和不 unlikely 有反应的转移性乳腺癌患者。
研究设计与样本
- 本文为综述,回顾18F-FES显像的基础、正常分布、假阳性与假阴性及最新临床应用。
主要发现
- 概念验证研究显示肿瘤18F-FES PET阳性与活检样本放射性配体结合及免疫组化评估的ER阳性状态具有预期相关性。
- 18F-FES PET/CT于2016年在法国、2020年在美国获批用于ER阳性转移性或复发性乳腺癌患者。
关键数值与推荐
- SNMMI 2023年适用标准认定18F-FES PET/CT的四个适用指征:活检困难或活检无诊断结果时评估转移灶功能性ER状态、其他影像检查不明确或可疑时检测ER状态、转移性疾病初始诊断、转移性疾病进展时考虑内分泌治疗。
临床怎么用
- 18F-FES PET/CT可用于评估ER阳性转移性或复发性乳腺癌患者的ER状态,以考虑内分泌治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-16α-Fluoroestradiol (18F-FES) is a radiolabeled estrogen analogue positron emission tomography (PET) imaging agent that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells. Proof-of-concept studies of 18F-FES demonstrated expected correlation between tumoral 18F-FES-positivity on PET-imaging and ER+ status assessed on biopsy samples by radioligand binding and immunohistochemistry. After decades of study, 18F-FES PET/CT gained clinical approval in 2016 in France and 2020 in the United States for use in patients with ER+ metastatic or recurrent breast cancer. ER+ as assessed by 18F-FES PET/CT has been shown to serve as a biomarker, identifying metastatic breast cancer patients who may respond to endocrine therapy and those who are unlikely to respond. In 2023, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) published Appropriate Use Criteria for 18F-FES PET/CT, identifying four indications in which use of 18F-FES PET/CT was "appropriate": (1) To assess functional ER status in metastatic lesions unfavorable to biopsy or when biopsy is nondiagnostic, (2) To detect ER status when other imaging tests are equivocal or suspicious, and at (3) initial diagnosis of metastatic disease or (4) progression of metastatic disease, for considering endocrine therapy. This article reviews the foundations of 18F-FES imaging, including normal distribution, false positives, and false negatives, and describes the most up-to-date clinical uses as well as emerging research in breast cancer and other patient populations.
引用
- O'Brien SR, Edmonds CE, Ward RE, et al. Update on 18F-Fluoroestradiol. Semin Nucl Med. 2024. PMID: 39368910. doi:10.1053/j.semnuclmed.2024.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。